ER-60 (PDIA3) is highly expressed in a newly established serous ovarian cancer cell line, YDOV-139.

Characterization of a newly established serous ovarian cancer cell line, YDOV-139 was performed and ER-60 (PDIA3), which was highly expressed in YDOV-139, was evaluated as novel biomarker for ovarian cancer. The YDOV-139 cell line was established using ascites samples from a 67-year-old Korean woman with recurrent ovarian cancer, and was characterized with respect to various biological and genetic features. Gene expression profiles were analyzed using cDNA microarrays, and proteomic evaluation was performed by two-dimensional gel electrophoresis (2-DE) and matrix-assisted laser desorption ionization-time of flight peptide mass fingerprinting (MALDI-TOF/PMF). Four candidate markers that were strongly up-regulated in YDOV-139 were validated by real-time polymerase chain reaction (PCR) and immunohistochemistry (IHC). The epithelial-like characteristics of YDOV-139 were evident from morphologic studies, and the average population doubling time was 120 h. When transplanted into nude mice, YDOV-139 cells successfully induced tumor masses in all three animals. Chemosensitivity tests showed that gemcitabine had the highest chemosensitivity index against YDOV-139 cells. HLA typing revealed A*24/A*31, B*07/B*35, Cw03*(09)/w*07, and DRB1*01/DRB1*15 alleles. Compared with human ovarian surface epithelial (HOSE) cells, 2,520 genes and 23 protein spots were differentially expressed in YDOV-139. Validation by real-time PCR showed that mRNA expression of LCN2, MDK, SLCO4A1, and ER-60 (PDIA3) were strongly elevated in ovarian cancers. In IHC analysis, ER-60 (PDIA3) was significantly overexpressed in both borderline tumors and invasive ovarian cancers (P<0.001). The molecular characteristics of YDOV-139 may have implications for future ovarian cancer research and ER-60 (PDIA3) should be investigated further as a potential biomarker of ovarian cancer.

[1]  Hanbyoul Cho,et al.  Lipocalin 2 Expressions Correlate Significantly With Tumor Differentiation in Epithelial Ovarian Cancer , 2009, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[2]  Patrick Dowd,et al.  Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families , 1994, Nature Genetics.

[3]  B. Seliger,et al.  Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. , 2000, Tissue antigens.

[4]  C. F. Bennett,et al.  Molecular cloning and complete amino-acid sequence of form-I phosphoinositide-specific phospholipase C , 1988, Nature.

[5]  J. Abramowicz,et al.  Anti‐Tumor Antibodies in Ovarian Cancer , 2005, American journal of reproductive immunology.

[6]  Maurice P H M Jansen,et al.  Molecular profiling of platinum resistant ovarian cancer , 2006, International journal of cancer.

[7]  D. Macer,et al.  Structure and assembly of the endoplasmic reticulum. , 1989, Biochemical Society transactions.

[8]  J. Smyth,et al.  Characterization and properties of nine human ovarian adenocarcinoma cell lines. , 1988, Cancer research.

[9]  J. W. Kim,et al.  Major clinical research advances in gynecologic cancer 2008. , 2008, Journal of gynecologic oncology.

[10]  R. L. Baldwin,et al.  Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT. , 2007, Gynecologic oncology.

[11]  A. Jemal,et al.  Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival , 2004, Cancer.

[12]  澁佐 隆.  Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma , 1998 .

[13]  A. Shevchenko,et al.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. , 1996, Analytical chemistry.

[14]  Jae Hoon Kim,et al.  Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma. , 2005, Gynecologic oncology.

[15]  P. Spellman,et al.  Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities , 2008, BMC Cancer.

[16]  S. Mok,et al.  Biomarker discovery in epithelial ovarian cancer by genomic approaches. , 2007, Advances in cancer research.

[17]  B. Vanderhyden,et al.  Models of ovarian cancer—Are we there yet? , 2005, Molecular and Cellular Endocrinology.

[18]  M. Lei.  The MCM complex: its role in DNA replication and implications for cancer therapy. , 2005, Current cancer drug targets.

[19]  K. Iida,et al.  Tissue distribution of ERp61 and association of its increased expression with IgG production in hybridoma cells. , 1994, Experimental cell research.

[20]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[21]  R. Bjerkvig,et al.  Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. , 2006, Cancer research.

[22]  H M Rosenberg,et al.  Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. , 2001, Journal of the National Cancer Institute.

[23]  Steven Eschrich,et al.  Elucidation of a protein signature discriminating six common types of adenocarcinoma , 2007, International journal of cancer.

[24]  E. Wardelmann,et al.  HLA‐class II haplotype associations with ovarian cancer , 2006, International journal of cancer.

[25]  C. Le Page,et al.  Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer , 2006, International journal of cancer.

[26]  I. Shih,et al.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. , 2004, The American journal of pathology.

[27]  C. Turano,et al.  Proteins of the PDI family: Unpredicted non‐ER locations and functions , 2002, Journal of cellular physiology.

[28]  J. Holden.  Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs. , 1997, Annals of clinical and laboratory science.

[29]  A. Venkitaraman,et al.  AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. , 2003, Cancer cell.

[30]  P. Oefner,et al.  Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. , 1999, Genomics.

[31]  R. Berkowitz,et al.  Osteopontin as a potential diagnostic biomarker for ovarian cancer. , 2002, JAMA.

[32]  Anil Potti,et al.  An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Hanbyoul Cho,et al.  Molecular characterization of a new ovarian cancer cell line, YDOV-151, established from mucinous cystadenocarcinoma. , 2009, The Tohoku journal of experimental medicine.

[34]  N. Yaegashi,et al.  Midkine and its clinical significance in endometrial carcinoma , 2008, Cancer science.

[35]  S. Minkin,et al.  High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. , 2005, Neoplasia.

[36]  Young Tae Kim,et al.  Genomic and proteomic characterization of YDOV-157, a newly established human epithelial ovarian cancer cell line , 2008, Molecular and Cellular Biochemistry.

[37]  G. Scambia,et al.  Biological characterization of ovarian cancer: prognostic and therapeutic implications. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  E. Petricoin,et al.  Biomarkers of ovarian tumours. , 2004, European journal of cancer.

[39]  S. Cannistra.  Cancer of the ovary. , 1993, The New England journal of medicine.

[40]  B. Yoo,et al.  Regulation of MDK expression in human cancer cells modulates sensitivities to various anticancer drugs: MDK overexpression confers to a multi-drug resistance. , 2007, Cancer letters.